World Market Leader in Biosimulation in CNS Drug Discovery & Development (Markets&Markets Nov2012) Mulhouse (France) and Cambridge (Massachusetts, USA)
Rhenovia Pharma SAS is a fully integrated biotechnology firm dedicated to global healthcare in the field of central and peripheral nervous system (C&PNS) developing innovative solutions for an improved quality of life of patients, their families and caregivers
- To PROTECT against prolonged exposure to neurotoxic agents as risk factors for diseases like Alzheimer (chemicals, agrochemicals, or pollutants in the Eco-toxicology environment) and acute exposure (protection of military personnel against chemical weapons and civilians against terrorist threats) - To PREVENT occurrence of neurodegenerative diseases by nutrition- health and wellness - To TREAT diseases by o optimizing the Drug Discovery and Development via its RHEDDOS™ service-partnership offerings to reduce costs, attrition rate and time-to-market o elaborating individualized drug and active compound delivery with its revolutionary rate controlled transdermal delivery device RHEPATCH™ o developing high performance analytical methods for the identification of drug efficacy biomarkers and side effects alerts
Rhenovia's differentiator: its unique Modeling & Simulation platforms RHENOMS™ HIPP and RHENOMS™ STRI integrating the complexity of neuronal biological systems and multifactorial nature of C&PNS pathologies. Rhenovia's strengths: interactive partnerships and strategic alliances with
Latest News: May 15th, 2012 2nd ROUND TABLE OF FUND RAISING Enters in its second phase with the opening of the capital to individuals,companies, foundations and investors excited by the developments of Rhenovia and loving to take part to the adventure.
Demonstration in 2 videos: http://www.industrie.com/it/pharmacie/rhenovia-s-t-imule-les-neurones.9971
|
|
